Biotech falls short of expectations

Citation metadata

Date: Dec. 2010
From: Pharmaceutical Technology Europe(Vol. 22, Issue 12)
Publisher: Intellisphere, LLC
Document Type: Article
Length: 637 words
Lexile Measure: 1260L

Document controls

Main content

Article Preview :

Biotech has had a profound impact on the pharma industry by helping to develop new medicines that treat patients more effectively; however, despite its achievements, it hasn't made a significant difference to the number of new treatments reaching the market. According to PricewaterhouseCoopers' (PwC) research paper, Biotech reinvented, biotech hasn't met the industry's expectations and will need to change its business model if it is to survive. Crucially, biotech hasn't reduced the inherent risk in drug discovery and development; the overall success rate is still only 9.1% for biotech drugs compared with 6.7% for a small-molecule drug.

Flawed business model

Unfortunately, biotech's situation worsens.

"The current business model on which biotech has relied is flawed," Simon Friend, Global Pharmaceuticals and Life Sciences Industry Leader at PwC, said in a statement. "Due to poor rates of return, investment has dried up and many of the external conditions that have allowed companies to thrive are vanishing."

In particular, the research base...

Source Citation

Source Citation   

Gale Document Number: GALE|A248735656